-
Something wrong with this record ?
Interplay between the APOE Genotype and Possible Plasma Biomarkers in Alzheimer's Disease
M. Zverova, E. Kitzlerova, Z. Fisar, R. Jirak, J. Hroudova, H. Benakova, P. Lelkova, P. Martasek, J. Raboch,
Language English Country United Arab Emirates
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Alzheimer Disease blood genetics MeSH
- Apolipoproteins E genetics MeSH
- Biomarkers blood MeSH
- Genotype MeSH
- Homocysteine blood MeSH
- Hydrocortisone blood MeSH
- Middle Aged MeSH
- Humans MeSH
- Melatonin blood MeSH
- Prolactin blood MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
BACKGROUND: Alzheimer's disease (AD) is a progressive neurodegenerative disorder with a complex pathogenesis and a common occurrence of comorbid diseases such as depression. It is accepted that the presence of the ε4 allele of the gene that encodes apolipoprotein E (APOE) is the strongest genetic risk factor for the development of sporadic AD. Melatonin, cortisol, homocysteine, and prolactin are presumed to be risk factors or biomarkers for stress- and age-related disorders. OBJECTIVE: The interplay between the APOE genotype and plasma biomarkers was examined in patients with AD presenting with or without depression to contribute to understanding the interdependence of various molecular mechanisms in the pathophysiology of AD. METHOD: The APOE genotype and morning plasma melatonin, cortisol, homocysteine, and prolactin concentrations were measured in 85 patients with AD and 44 elderly controls. RESULTS: A significant association between AD and the allele (ε4) or genotype (ε3/ε4 or ε4/ε4) frequencies of APOE was confirmed. Plasma homocysteine and cortisol levels were significantly increased in patients with AD compared to those in controls, independent of the presence of comorbid depressive symptoms or the severity of dementia. Significantly lower plasma melatonin concentration was found in patients with AD but not in controls, who were noncarriers of the APOE ε4 allele, regardless of the presence of depression or the severity of dementia in AD. CONCLUSION: Our findings indicate the existence of a little-known specific APOE-mediated mechanism that increases the plasma melatonin level in a subgroup of patients with AD who are carriers of the APOE ε4 allele.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19045432
- 003
- CZ-PrNML
- 005
- 20200113082217.0
- 007
- ta
- 008
- 200109s2018 ts f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.2174/1567205015666180601090533 $2 doi
- 035 __
- $a (PubMed)29852871
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ts
- 100 1_
- $a Zverova, Martina $u Department of Psychiatry, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
- 245 10
- $a Interplay between the APOE Genotype and Possible Plasma Biomarkers in Alzheimer's Disease / $c M. Zverova, E. Kitzlerova, Z. Fisar, R. Jirak, J. Hroudova, H. Benakova, P. Lelkova, P. Martasek, J. Raboch,
- 520 9_
- $a BACKGROUND: Alzheimer's disease (AD) is a progressive neurodegenerative disorder with a complex pathogenesis and a common occurrence of comorbid diseases such as depression. It is accepted that the presence of the ε4 allele of the gene that encodes apolipoprotein E (APOE) is the strongest genetic risk factor for the development of sporadic AD. Melatonin, cortisol, homocysteine, and prolactin are presumed to be risk factors or biomarkers for stress- and age-related disorders. OBJECTIVE: The interplay between the APOE genotype and plasma biomarkers was examined in patients with AD presenting with or without depression to contribute to understanding the interdependence of various molecular mechanisms in the pathophysiology of AD. METHOD: The APOE genotype and morning plasma melatonin, cortisol, homocysteine, and prolactin concentrations were measured in 85 patients with AD and 44 elderly controls. RESULTS: A significant association between AD and the allele (ε4) or genotype (ε3/ε4 or ε4/ε4) frequencies of APOE was confirmed. Plasma homocysteine and cortisol levels were significantly increased in patients with AD compared to those in controls, independent of the presence of comorbid depressive symptoms or the severity of dementia. Significantly lower plasma melatonin concentration was found in patients with AD but not in controls, who were noncarriers of the APOE ε4 allele, regardless of the presence of depression or the severity of dementia in AD. CONCLUSION: Our findings indicate the existence of a little-known specific APOE-mediated mechanism that increases the plasma melatonin level in a subgroup of patients with AD who are carriers of the APOE ε4 allele.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a Alzheimerova nemoc $x krev $x genetika $7 D000544
- 650 _2
- $a apolipoproteiny E $x genetika $7 D001057
- 650 _2
- $a biologické markery $x krev $7 D015415
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a genotyp $7 D005838
- 650 _2
- $a homocystein $x krev $7 D006710
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hydrokortison $x krev $7 D006854
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a melatonin $x krev $7 D008550
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a prolaktin $x krev $7 D011388
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Kitzlerova, Eva $u Department of Psychiatry, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
- 700 1_
- $a Fisar, Zdenek $u Department of Psychiatry, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
- 700 1_
- $a Jirak, Roman $u Department of Psychiatry, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
- 700 1_
- $a Hroudova, Jana $u Department of Psychiatry, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
- 700 1_
- $a Benakova, Hana $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
- 700 1_
- $a Lelkova, Petra $u Department of Pediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
- 700 1_
- $a Martasek, Pavel $u Department of Pediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
- 700 1_
- $a Raboch, Jiri $u Department of Psychiatry, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
- 773 0_
- $w MED00008816 $t Current Alzheimer research $x 1875-5828 $g Roč. 15, č. 10 (2018), s. 938-950
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29852871 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200109 $b ABA008
- 991 __
- $a 20200113082549 $b ABA008
- 999 __
- $a ok $b bmc $g 1483701 $s 1084105
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 15 $c 10 $d 938-950 $e - $i 1875-5828 $m Current Alzheimer research $n Curr Alzheimer Res $x MED00008816
- LZP __
- $a Pubmed-20200109